Roche Holding AG (OTC: RHHBY)

Roche is the world's largest biotech company and a top-three pharma player, with about CHF 59 billion (~$66 billion) in annual revenue. The Swiss company dominates oncology with drugs like Tecentriq, Perjeta, and Herceptin, and its diagnostics division is the global leader in in-vitro diagnostics. Roche's unique structure — a publicly traded company controlled by the founding Hoffmann and Oeri families — gives it unusual long-term strategic freedom.

Two divisions: Pharmaceuticals (~75% of revenue) and Diagnostics (~25%). The pharma business focuses on oncology, immunology, neuroscience, and ophthalmology. Diagnostics provides testing instruments and reagents to hospitals and labs worldwide. The combination of pharma and diagnostics enables a "personalized healthcare" strategy — test to identify the right patients, then treat them with targeted therapies.

Fritz Hoffmann-La Roche founded the company in Basel, Switzerland in 1896. Roche acquired a majority stake in Genentech in 1990 and fully acquired it in 2009 for $47 billion — gaining access to pioneering biotech capabilities. The company's diagnostics division played a critical role during COVID with PCR testing. Roche has been navigating biosimilar competition to its older blockbusters while building the next generation of therapies.